吗替麦考酚酯和麦考酚钠用于肾移植后免疫抑制的药物经济学评价  

Pharmacoeconomic Evaluation of Mycophenolate Mofetil and Enteric-coated Mycophenalate Sodium for Immuno-suppression after Renal Transplantation

作　　者：谢颖[1] 宗欣[1] 陈丽[1] 刘玉聪[1] 张宁宁[1] 孙倩[1] 孙利华[1] 

机构地区：[1]沈阳药科大学工商管理学院孙利华工作室,沈阳110016

出　　处：《中国卫生经济》2011年第3期94-96,共3页Chinese Health Economics

摘　　要：目的:对吗替麦考酚酯和麦考酚钠用于肾移植后免疫抑制进行药物经济学评价。方法:基于社会视角,采用二次文献研究和模型研究方法,根据接受肾移植后患者健康状态发展规律,构建Markov模型,以成本效果比、成本效用比作为评价指标,并对结果进行敏感度分析。结果:在10个模型周期内,EC-MPS组肾移植患者获得的生命年和质量调整生命年分别为8.4年和6.1年,MMF组为7.5年和5.0年。EC-MPS组肾移植患者每获得一个生命年和质量调整生命年需付出的年医疗费用分别为47 936元和66 011元,MMF组为63 513元和95 270元。结论:EC-MPS用于肾移植后免疫抑制较MMF更具有成本效果。Objective： To evaluate the cost-effectiveness of Mycophenolate mofetil and Enteric-coated Mycophenalate Sodium for immunosuppression after renal transplantation. Methods： The evaluation is based on social perspective. A markov model is constructed to simulate the development of the health status of patients after kidney transplantation. Cost-effectiveness ratio and cost-utility ratio are used as the evaluation indicators in the study. Sensitivity analysis is done to make sure that the conclusion is reliable. Results： Within ten cycles of the model, the life years and the quality-adjusted life year （QALY） of the EC-MPS group patient are 8.4 and 6.3 years respectively, and the MMF group patient are 7.5 and 3 years respectively. It costs 47 936 and 66 011 yuan to obtain every life year and every QALY for the patients of EC-MPS group, while the cost for patients of MMF group are 63 513 and 95 270 yuan respectively. Conclusion： The EC-MPS has more cost effectiveness than the MMF when is used for immunosuppression after renal transplantation.

关 键 词：肾移植 麦考酚钠 吗替麦考酚酯 药物经济学评价 马尔可夫模型 

分 类 号：R699[医药卫生—泌尿科学]